Biomarkers in castration-resistant prostate cancer

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 2, 2014, Pages 115-118

  Armstrong, Andrew J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN; TRASTUZUMAB;

CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CASTRATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG DESIGN; HUMAN; NOTE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY CONTROL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84896725367     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61(3):549-559.
2. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
3. Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.
4. Scher HI, Heller G, Molina A, et al. Evaluation of a composite biomarker panel including circulating tumor cell enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer. Paper presented at: European Cancer Congress 2013; September 27-October 1, 2013; Amsterdam, the Netherlands. Abstract 2851.